Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Gains from Sales and Divestitures (2016 - 2017)

Tenax Therapeutics' Gains from Sales and Divestitures history spans 5 years, with the latest figure at $116525.0 for Q3 2017.

  • For Q3 2017, Gains from Sales and Divestitures rose 48452.08% year-over-year to $116525.0; the TTM value through Sep 2017 reached $116525.0, up 48452.08%, while the annual FY2016 figure was $16.0, N/A changed from the prior year.
  • Gains from Sales and Divestitures for Q3 2017 was $116525.0 at Tenax Therapeutics, roughly flat from $116525.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $116525.0 in Q2 2017 and bottomed at -$17700.0 in Q3 2014.
  • The 5-year median for Gains from Sales and Divestitures is $15590.0 (2013), against an average of $31900.2.
  • The largest annual shift saw Gains from Sales and Divestitures crashed 1378.9% in 2014 before it surged 151163.64% in 2017.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $50062.0 in 2013, then crashed by 40.48% to $29796.0 in 2014, then tumbled by 99.42% to $174.0 in 2015, then crashed by 90.8% to $16.0 in 2016, then surged by 728181.25% to $116525.0 in 2017.
  • Per Business Quant, the three most recent readings for TENX's Gains from Sales and Divestitures are $116525.0 (Q3 2017), $116525.0 (Q2 2017), and $116473.0 (Q1 2017).